1. What is it?
GLP-1 is a peptide hormone made by the body, including in the intestines. It is one of the hormones that helps tell the pancreas that a meal has arrived. This means the response to food involves more than just a rise in blood sugar. The abbreviation is also used informally for a group of medicines. In this profile, it refers to the natural hormone; semaglutide and other medicinal substances have their own properties and separate profiles. [185] [181]
2. Why do people turn to it?
People usually search GLP-1 to understand obesity treatment, reduced appetite or diabetes control. Medicine uses this system through GLP-1 receptor drugs, including semaglutide in specific approved products. Indications concern a particular medicine and patient group. GLP-1 in a product description alone does not prove effectiveness, composition or treatment approval. [181]
3. How does it work?
GLP-1 helps increase insulin release in response to glucose and contributes to the regulation of fullness. In human experiments, it also affected the rate of stomach emptying. The natural hormone breaks down quickly, partly through an enzyme called DPP-4. This is an important difference between a brief physiological signal and the effect of a specially developed medicine. Changes to a substance's structure or formulation can alter how long it acts, so the names should not be used interchangeably. [185] [179] [180]
4. What do studies actually show?
A 1998 paper studied natural GLP-1 in 20 healthy men, assessing fullness and food intake. Another small experiment followed eight men with obesity for several hours. The results helped establish the hormone's connection with appetite and digestion. These were not long-term obesity-treatment studies. They cannot predict how many kilograms someone will lose or how long the change will last. [178] [179]
5. What do we still not know?
Feeling less hungry during a short experiment is different from safely treating a chronic condition for many months. Small studies of natural GLP-1 help explain physiology, but they do not replace clinical trials of specific products. Results for one medicine also do not automatically describe every substance acting on this receptor. Relevant factors include the molecule's structure, how long it acts, the people studied and whether researchers assessed weight, blood sugar or other health outcomes. These details determine what can reliably be concluded. [178] [180] [181]
6. What are the risks?
A hormonal signal's natural origin does not mean every product mimicking it is risk-free. Look for side-effect information under the specific medicine's name. For example, medicines acting on the GLP-1 receptor may cause digestive symptoms, and suitability depends on a person's health. There is no universal safety guide for everything called GLP-1 online. Identifying the substance is the first step towards understanding this information. [181]
7. Is it an approved medicine?
GLP-1 names a natural hormone, not one approved product. The EU has approved medicines using its receptor, including Wegovy containing semaglutide. Approval applies to a specific product and its indications, not every substance or mixture bearing this abbreviation. Approval, benefits and contraindications must therefore always be linked to the full medicine name and the country concerned. [181]
8. What is new in research?
As of 3 November 2026, news about GLP-1 largely concerns the development of medicines, new formulations and uses. It does not mean the natural hormone has been rediscovered. When reading a report, it is worth checking the full name of the substance tested and who was studied. Discovering how a signal works in the body helps in designing a medicine, but does not establish all its benefits. [181] [178] [180]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
Physiological experiment in healthy volunteers; PubMed abstract read; source concerning natural hormones. Accessed: 03.11.2026.
- Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
Experiment in 20 healthy men; 01.02.1998; PubMed abstract read · DOI: 10.1172/JCI990. Accessed: 03.11.2026.
- Wegovy
EMA; current description of semaglutide and its indications reviewed on 3 November 2026; product page, not a source of results for natural GLP-1. Accessed: 3 November 2026.
- Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
Short experiment in 8 men with obesity; March 1999; PubMed abstract read · DOI: 10.1038/sj.ijo.0800818. Accessed: 03.11.2026.
- Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
Study of natural GLP-1 metabolism; March 1995; full PubMed abstract reviewed through the search index · DOI: 10.1210/jcem.80.3.7883856. Accessed: 3 November 2026.